Table 1:
Demographic table of recruited patients: Asthma and COPD
| Asthma | COPD | |
|---|---|---|
| N | 16 | 23 |
| Age (mean, SD) | 62 (10) | 64 (11) |
| Sex (F, n, % of n) | 9 (56) | 10 (43) |
| FEV1 %Pred (mean, SD) | 65 (17)* | 49 (17)* |
| FEV1/FVC (mean, SD) | 0.62 (0.13)* | 0.49 (0.13)* |
| DLCO %Pred (mean, SD) | 99 (33)*† | 61 (18) *†† |
| Current Smoking (n, % of n) | 1 (6)* | 12 (52)* |
| Previous Smoking (n, % of n) | 0 (0) | 7 (30) |
| Smoking History in pack-years (mean, SD) | N/A | 46 (24) |
| Emphysema (n, % of n) | 1 (6)* | 15 (65)* |
| Centrilobular (n) | 1 | 7 |
| Paraseptal (n) | 0 | 1 |
| Both (n) | 0 | 7 |
| Eosinophilia (n, % of n) | 11 (69) | 11 (48) |
| Sputum eosinophil% (mean, SD) | 7.0 (9.1) | 5.9 (15) |
| Sputum EPX (ng/mL-g; mean, SD) | 375 (587)* | 91.4 (144)* |
| ICS dose (median, max-min) | 750 (2000, 0) | 750 (3500, 0) |
| ICS use (n, % of n) | 15 (94) | 20 (87) |
| OCS use (n, % of n) | 5 (31) | 2 (9) |
| LABA use (n, % of n) | 15 (94) | 18 (83) |
| LAMA use (n, % of n) | 0 (0)* | 12 (52)* |
*
denotes statistically significant difference between groups
†
based on n=3
††
based on n=9
SD – standard deviation; FEV1 – forced expiratory volume in 1 second; FVC – forced vital capacity; EPX – eosinophil peroxidase; ICS – inhaled corticosteroid dose, daily mcg equivalent for fluticasone; OCS – on maintenance oral corticosteroid; LABA – long acting beta-agonists; LAMA : long acting muscarinic antagonists. All COPD patients are current smokers or ex-smokers with >10 pack year history.